Prince Group Research
Our research focuses on the identification and characterisation of novel therapeutic interventions and drug targets for the treatment of cancer. To this end, we have focussed on the homologous T-box transcription factors TBX2 and TBX3, which are overexpressed in a range of cancers, and we have published papers on their role and regulation in breast cancer, melanoma and sarcomas. Indeed, together with other groups, we have identified TBX2 as a powerful anti-senescence and pro-proliferative factor with a role in anticancer drug resistance and a critical role for TBX3 in tumour formation and invasion. These results have highlighted their potential as novel targets in the development of effective cancer therapy. We are also investigating the potential of organometallic compounds as novel anticancer drugs and repositioning anti-malarial and anti-psychotic drugs for anticancer activity.